Mitchell Capital Management Co. Makes New Investment in Johnson & Johnson $JNJ

Mitchell Capital Management Co. purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the third quarter, Holdings Channel reports. The institutional investor purchased 4,771 shares of the company’s stock, valued at approximately $885,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. increased its holdings in Johnson & Johnson by 0.3% in the 3rd quarter. Eubel Brady & Suttman Asset Management Inc. now owns 141,759 shares of the company’s stock worth $26,285,000 after purchasing an additional 458 shares in the last quarter. Savvy Advisors Inc. boosted its stake in shares of Johnson & Johnson by 2.3% during the third quarter. Savvy Advisors Inc. now owns 22,715 shares of the company’s stock valued at $4,212,000 after purchasing an additional 501 shares in the last quarter. Onyx Bridge Wealth Group LLC grew its holdings in shares of Johnson & Johnson by 25.9% during the third quarter. Onyx Bridge Wealth Group LLC now owns 5,731 shares of the company’s stock worth $1,063,000 after purchasing an additional 1,178 shares during the last quarter. TPG Advisors LLC raised its holdings in Johnson & Johnson by 3.5% in the 3rd quarter. TPG Advisors LLC now owns 1,628 shares of the company’s stock valued at $302,000 after buying an additional 55 shares during the last quarter. Finally, Cibc World Market Inc. boosted its position in Johnson & Johnson by 2.0% during the 3rd quarter. Cibc World Market Inc. now owns 505,487 shares of the company’s stock worth $93,727,000 after buying an additional 10,023 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $240.97 on Thursday. The firm has a market cap of $580.56 billion, a PE ratio of 21.81, a price-to-earnings-growth ratio of 2.31 and a beta of 0.35. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average price of $215.57 and a 200-day moving average price of $195.51. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $241.26.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on JNJ shares. The Goldman Sachs Group restated a “buy” rating and issued a $250.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Wolfe Research boosted their price objective on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Daiwa Securities Group upped their price target on Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Royal Bank Of Canada raised their price objective on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.